A61K 31/402
1-aryl substituted
Official title: 1-aryl substituted, e.g. piretanide
A61K31/402 (1-aryl substituted) appears on 242 US grants and 387 published applications in this corpus.
Search patents in A61K- Granted patents
- 242
- Published applications
- 387
- Assignees
- 228
- Inventors
- 927
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 2 |
| 2003 | 1 | 7 |
| 2004 | 5 | 7 |
| 2005 | 3 | 10 |
| 2006 | 3 | 6 |
| 2007 | 4 | 8 |
| 2008 | 3 | 7 |
| 2009 | 7 | 10 |
| 2010 | 6 | 13 |
| 2011 | 3 | 12 |
| 2012 | 9 | 17 |
| 2013 | 15 | 22 |
| 2014 | 15 | 22 |
| 2015 | 19 | 28 |
| 2016 | 16 | 33 |
| 2017 | 22 | 23 |
| 2018 | 13 | 21 |
| 2019 | 21 | 25 |
| 2020 | 17 | 14 |
| 2021 | 17 | 13 |
| 2022 | 5 | 16 |
| 2023 | 8 | 21 |
| 2024 | 7 | 17 |
| 2025 | 8 | 18 |
| 2026 | 4 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles4 Aug 2026US 12,697,310 B2Montefiore Medical Center
- Polymorphs of phenyl pyrrole aminoguandium salts23 Jun 2026US 12,661,336 B2Synact Pharma APS
- Compound as a UBR box domain ligand24 Feb 2026US 12,559,455 B2Autotac Inc.
- Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy6 Jan 2026US 12,514,834 B2Kyoto University
- Compound as a UBR box domain ligand30 Dec 2025US 12,509,420 B2Autotac Inc.
- Combination therapies using immuno-dash inhibitors and pge2 antagonists17 Sep 2026US 2026/0272880 A1Trustees of Tufts College
- Novel co-drug, co-administration, and sequential administration of bispecific rbp4/ttr ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and ttr amyloidosis3 Sep 2026US 2026/0256818 A1Rensselaer Polytechnic Institute
- Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)27 Aug 2026US 2026/0248770 A1Children's Medical Center Corporation
- Chemical coupling linker and use thereof13 Aug 2026US 2026/0232832 A1
- Erap1 modulating compounds16 Jul 2026US 2026/0199455 A1Grey Wolf Therapeutics Limited
Most cited
By later US patents
- Method for enhancing outflow of aqueous humor in treatment of glaucoma151US 6,228,873 B1The Regents of the University of California · 2001
- Npyy5 antagonists74US 6,699,891 B1Shionogi & Co., Ltd. · 2004
- Method for enhancing outflow of aqueous humor in treatment of glaucoma58US 5,763,491 AThe Regents of the University of California · 1998
- Inhibitors of histone deacetylase52US 7,816,363 B2Janssen Pharmaceutica NV · 2010
- Inhibitors of histone deacetylase47US 7,615,553 B2Janssen Pharmaceutica NV · 2009